Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions

Overview

Journal Antibodies (Basel)

Date 2024 Oct 25

PMID 39449330

Authors

Kinsley Wang

Robert Hsu

Affiliations

Soon will be listed here.

Abstract

Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally, though advances in targeted therapies have improved treatment outcomes. The mesenchymal-epithelial transition () gene plays a significant role in NSCLC, often through protein overexpression, exon 14 skipping mutations, and gene amplification, many of which arise as resistance mechanisms to other oncogenic drivers like epidermal growth factor receptor () mutations. This review examines the development and clinical efficacy of anti-MET antibody therapies. A comprehensive literature search was conducted using major medical databases looking at key relevant studies on anti-MET antibody studies. Both authors reviewed the literature, assessed study quality, and interpreted the results from each study. Amivantamab, a bispecific EGFR/MET antibody was approved to treat EGFR exon 20 insertion and now has recently been extended to target classical EGFR mutations with progression on osimertinib. Other important anti-MET targeted therapies in development include antibody drug conjugates such as telisotuzumab vedotin, REGN5093-M114, and AZD9592 and emibetuzumab, which is a humanized immunoglobulin G4 monoclonal bivalent MET antibody. MET plays a significant role in NSCLC and amivantamab along with other anti-MET targeted therapies play a role in directly targeting MET and addressing acquired resistance to oncogenic drivers. Future research should focus on developing novel MET antibody drugs and exploring new therapeutic combinations to enhance treatment efficacy and overcome resistance in NSCLC. Refining biomarker-driven approaches to ensure precise patient selection is also critical to optimizing treatment outcomes.

Citing Articles

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

Liao Y, Tsai C, Huang H Cancers (Basel). 2025; 17(3).

PMID: 39941826 PMC: 11815769. DOI: 10.3390/cancers17030459.

References

Recondo G, Bahcall M, Spurr L, Che J, Ricciuti B, Leonardi G . Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020; 26(11):2615-2625. DOI: 10.1158/1078-0432.CCR-19-3608. View

Strickler J, Weekes C, Nemunaitis J, Ramanathan R, Heist R, Morgensztern D . First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018; 36(33):3298-3306. DOI: 10.1200/JCO.2018.78.7697. View

Coleman N, Hong L, Zhang J, Heymach J, Hong D, Le X . Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open. 2021; 6(6):100319. PMC: 8637467. DOI: 10.1016/j.esmoop.2021.100319. View

Yu H, Suzawa K, Jordan E, Zehir A, Ni A, Kim R . Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clin Cancer Res. 2018; 24(13):3108-3118. PMC: 6420806. DOI: 10.1158/1078-0432.CCR-17-2961. View

Camidge D, Barlesi F, Goldman J, Morgensztern D, Heist R, Vokes E . Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 41(5):1105-1115. PMC: 9928626. DOI: 10.1200/JCO.22.00739. View

Rosen L, Goldman J, Algazi A, Turner P, Moser B, Hu T . A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clin Cancer Res. 2016; 23(8):1910-1919. DOI: 10.1158/1078-0432.CCR-16-1418. View

Suda K, Onozato R, Yatabe Y, Mitsudomi T . EGFR T790M mutation: a double role in lung cancer cell survival?. J Thorac Oncol. 2008; 4(1):1-4. DOI: 10.1097/JTO.0b013e3181913c9f. View

Schoenfeld A, Chan J, Kubota D, Sato H, Rizvi H, Daneshbod Y . Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in -Mutant Lung Cancer. Clin Cancer Res. 2020; 26(11):2654-2663. PMC: 7448565. DOI: 10.1158/1078-0432.CCR-19-3563. View

Leighl N, Akamatsu H, Lim S, Cheng Y, Minchom A, Marmarelis M . Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024; 42(30):3593-3605. PMC: 11469630. DOI: 10.1200/JCO.24.01001. View

10.

Riedel R, Fassunke J, Tumbrink H, Scheel A, Heydt C, Hieggelke L . Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. Eur J Cancer. 2022; 179:124-135. DOI: 10.1016/j.ejca.2022.11.010. View

11.

Zappa C, Mousa S . Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016; 5(3):288-300. PMC: 4931124. DOI: 10.21037/tlcr.2016.06.07. View

12.

Scagliotti G, Moro-Sibilot D, Kollmeier J, Favaretto A, Cho E, Grosch H . A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients. J Thorac Oncol. 2019; 15(1):80-90. DOI: 10.1016/j.jtho.2019.10.003. View

13.

Jorgensen J, Mollerup J . Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers (Basel). 2022; 14(9). PMC: 9105764. DOI: 10.3390/cancers14092150. View

14.

Oh S, Lee Y, Lee E, Kim J, Park Y, Heo S . Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res. 2022; 29(1):221-232. DOI: 10.1158/1078-0432.CCR-22-2180. View

15.

Mitsudomi T, Yatabe Y . Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98(12):1817-24. PMC: 11159145. DOI: 10.1111/j.1349-7006.2007.00607.x. View

16.

Naldini L, Weidner K, Vigna E, Gaudino G, Bardelli A, Ponzetto C . Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991; 10(10):2867-78. PMC: 452997. DOI: 10.1002/j.1460-2075.1991.tb07836.x. View

17.

Wakelee H, Zvirbule Z, De Braud F, Kingsley C, Mekhail T, Lowe T . Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016; 18(1):50-59. DOI: 10.1016/j.cllc.2016.09.013. View

18.

Huang L, Fu L . Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015; 5(5):390-401. PMC: 4629442. DOI: 10.1016/j.apsb.2015.07.001. View

19.

Spigel D, Edelman M, OByrne K, Paz-Ares L, Mocci S, Phan S . Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. J Clin Oncol. 2016; 35(4):412-420. DOI: 10.1200/JCO.2016.69.2160. View

20.

Belzer A, Nguyen M, Talsania A, Haldas J, Smith J, Leventhal J . Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use. JAMA Dermatol. 2022; 159(1):109-111. PMC: 9685543. DOI: 10.1001/jamadermatol.2022.4466. View